David de Graaf has a new gig, a new idea and a new startup — hunting some new money
David de Graaf has a new gig at the helm of a tiny biotech startup. And he has some big plans to pursue an unusual pathway in drug development.
You may remember that de Graaf had been CEO at Syntimmune, leaving the company shortly before Alexion swooped in and bought the rare-disease biotech for $1.2 billion. Last fall, he stepped up to take charge of a small company in the Netherlands.
In short order, he changed the name to Comet and set up a new HQ in Cambridge, MA — 3 of the 5-member startup team are still in the Netherlands — and now the ex-Apple Tree partner has hit the circuit looking to raise a launch round for his new endeavor, with plans to boost the staff to about 20 people.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.